A08-Respuesta Inmune y Cáncer

Información
Miembros
Publicaciones
Proyectos
Ensayos clínicos

El grupo está involucrado en el análisis de la respuesta inmunitaria en el cáncer, el papel de los leucocitos infiltrantes y las características inmunofenotípicas de las células tumorales. El grupo de investigación ha identificado los principales mecanismos de escape que utilizan los tumores (cáncer renal, vejiga, próstata y colon) para eludir la respuesta inmunitaria. Particularmente se ha centrado en aquellos mecanismos que impiden el reconocimiento antigénico por los efectores citotóxicos inmunitarios. Se han evaluado los aspectos más relevantes que estos defectos tienen en diversos protocolos de inmunoterapia y la corrección posible, mediante procedimientos de terapia génica. El grupo colabora con diversos centros europeos y americanos que trabajan en el diseño de vacunas contra el cáncer

Palabras clave

Escape Inmunológico del Cáncer, Inmunoterapia, Terapia Génica

HERNANI GIL JULIO

JOSE RAMON VILCHEZ GUTIERREZ

ANA BELEN RODRIGUEZ MARTIN

VERONICA SANZ SERRANO

MARIA JOSE OLIVARES DURAN

ANTONIO RODRIGUEZ NICOLAS

ORCID

TERESA RODRIGUEZ RUIZ

ORCID

JOSE MARIA ROMERO NOGUERA

FRANCISCO RUIZ-CABELLO OSUNA

ORCID

FERNANDO VAZQUEZ ALONSO

ORCID

FRANCISCO JAVIER VICENTE PRADOS

NATALIA APTSIAURI

ORCID

MONICA BERNAL SANCHEZ

JOSE MANUEL COZAR OLMO

ANGEL MIGUEL GARCIA LORA

ORCID

JUAN FRANCISCO GUTIERREZ BAUTISTA

PILAR JIMENEZ GAMIZ

FRANCISCO JAVIER PEREA GARCIA

ORCID

PER ANDERSON

ORCID

Hidalgo-García, L; Ruiz-Malagon, AJ; Huertas, F; Rodríguez-Sojo, MJ; Molina-Tijeras, JA; Diez-Echave, P; Becerra, P; Mirón, B; Morón, R; Rodríguez-Nogales, A; Gálvez, J; Rodríguez-Cabezas, ME; Anderson, P

Administration of intestinal mesenchymal stromal cells reduces colitis-associated cancer in C57BL/6J mice modulating the immune response and gut dysbiosis

PHARMACOLOGICAL RESEARCH, 2023;

FI:9,3; D1

Alvarez-Gonzalez, B; Porras-Quesada, P; Arenas-Rodríguez, V; Tamayo-Gómez, A; Vázquez-Alonso, F; Martínez-Gonzalez, LJ; Hernández, AF; Alvarez-Cubero, MJ

Genetic variants of antioxidant and xenobiotic metabolizing enzymes and their association with prostate cancer: A meta-analysis and functional in silico analysis

SCIENCE OF THE TOTAL ENVIRONMENT, 2023;

FI:9,8; D1

Lozano-Lorca, M; Olmedo-Requena, R; Barrios-Rodríguez, R; Jiménez-Pacheco, A; Vázquez-Alonso, F; Castillo-Bueno, HM; Rodríguez-Barranco, M; Jiménez-Moleón, JJ

Ejaculation Frequency and Prostate Cancer: CAPLIFE Study

WORLD JOURNAL OF MENS HEALTH, 2023;

FI:4,8; D1

Alvarez-Cubero, MJ; Arance, E; de Santiago, E; Sanchez, P; Sepúlveda, MR; Marrero, R; Lorente, JA; Gonzalez-Cabezuelo, JM; Cuenca-Lopez, S; Cozar, JM; Vazquez-Alonso, F; Martinez-Gonzalez, LJ

Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels of S100A4 as a Detector in Plasma

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023;

FI:5,6; Q1

Ruiz-Cabello, FJM; Fusco, S; Ibáñez-Ibáñez, P; Guerrero-Vacas, G; Cabrerizo-Vílchez, MA; Rodríguez-Valverde, MA

Water-Repellent Galvanized Steel Surfaces Obtained by Sintering of Zinc Nanopowder

LANGMUIR, 2023;

FI:3,9; Q2

Rodriguez-Martinez, A; Simon-Saez, I; Perales, S; Garrido-Navas, C; Russo, A; De Miguel-Perez, D; Puche-Sanz, I; Alaminos, C; Ceron, J; Lorente, JA; Molina, MP; Gonzalez, C; Cristofanilli, M; Ortigosa-Palomo, A; Real, PJ; Rolfo, C; Serrano, MJ

Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior

THERANOSTICS, 2022;

FI:11,6; D1

Martin-Way, D; Puche-Sanz, I; Cozar, JM; Zafra-Gomez, A; Gomez-Regalado, MDC; Morales-Alvarez, CM; Hernandez, AF; Martinez-Gonzalez, LJ; Alvarez-Cubero, MJ

Genetic variants of antioxidant enzymes and environmental exposures as molecular biomarkers associated with the risk and aggressiveness of bladder cancer

SCIENCE OF THE TOTAL ENVIRONMENT, 2022;

FI:10,753; D1

Aptsiauri, N; Garrido, F

The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes

CLINICAL CANCER RESEARCH, 2022;

FI:13,801; D1

Rajwa, P; Maggi, M; Puche-Sanz, I; Rempega, G; Shariat, SF; Zattoni, F

Comment on: Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society

MINERVA UROLOGY AND NEPHROLOGY, 2022;

FI:5,214; Q1

Arance, E; Ramirez, V; Rubio-Roldan, A; Ocana-Peinado, FM; Romero-Cachinero, C; Jodar-Reyes, AB; Vazquez-Alonso, F; Martinez-Gonzalez, LJ; Alvarez-Cubero, MJ

Determination of Exosome Mitochondrial DNA as a Biomarker of Renal Cancer Aggressiveness.

CANCERS, 2022;

FI:6,575; Q1

Munoz-Herrera, CM; Gutierrez-Bautista, JF; Lopez-Nevot, MA

Clinical Case: Patient with Mixed Graft Rejection Four Days after Kidney Transplantation Developed Specific Antibodies against Donor Bw4 Specificities

ANTIBODIES, 2021;

Garzon, I; Jaimes-Parra, BD; Pascual-Geler, M; Cozar, JM; Sanchez-Quevedo, MD; Mosquera-Pacheco, MA; Sanchez-Montesinos, I; Fernandez-Valades, R; Campos, F; Alaminos, M

Biofabrication of a Tubular Model of Human Urothelial Mucosa Using Human Wharton Jelly Mesenchymal Stromal Cells

POLYMERS, 2021;

FI:4,329; Q1

Garrido, MA; Perea, F; Vilchez, JR; Rodriguez, T; Anderson, P; Garrido, F; Ruiz-Cabello, F; Aptsiauri, N

Copy Neutral LOH Affecting the Entire Chromosome 6 Is a Frequent Mechanism of HLA Class I Alterations in Cancer

CANCERS, 2021;

FI:6,639; Q1

Simon, I; Perales, S; Casado-Medina, L; Rodriguez-Martinez, A; Garrido-Navas, MD; Puche-Sanz, I; Diaz-Mochon, JJ; Alaminos, C; Lupianez, P; Lorente, JA; Serrano, MJ; Real, PJ

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation

CANCERS, 2021;

FI:6,639; Q1

Olmo, JMC; Rodriguez, JC; Rubio-Briones, J; Rodriguez, EU; del Toro, JM; Garcia-Porrero, AG; Juarez-Soto, A

Clinical drivers for imaging testing in non-metastatic castration-resistant prostate cancer in clinical practice: Results of the IDENTIFICA study

ACTAS UROLOGICAS ESPANOLAS, 2021;

FI:0,994; Q4

Martinez-Gonzalez, LJ; Antunez-Rodriguez, A; Vazquez-Alonso, F; Hernandez, AF; Alvarez-Cubero, MJ

Genetic variants in xenobiotic detoxi fication enzymes, antioxidant defenses and hormonal pathways as biomarkers of susceptibility to prostate cancer

SCIENCE OF THE TOTAL ENVIRONMENT, 2020;

FI:6,551; D1

Cano-Ibanez, N; Barrios-Rodriguez, R; Lozano-Lorca, M; Vazquez-Alonso, F; Arrabal-Martin, M; Trivino-Juarez, JM; Salcedo-Bellido, I; Jimenez-Moleon, JJ; Olmedo-Requena, R

Dietary Diversity and Prostate Cancer in a Spanish Adult Population: CAPLIFE Study

NUTRIENTS, 2020;

FI:4,546; Q1

Carrillo-Galvez, AB; Galvez-Peisl, S; Gonzalez-Correa, JE; de Haro-Carrillo, M; Ayllon, V; Carmona-Saez, P; Ramos-Mejia, V; Galindo-Moreno, P; Cara, FE; Granados-Principal, S; Munoz, P; Martin, F; Anderson, P

GARP is a key molecule for mesenchymal stromal cell responses to TGF-beta and fundamental to control mitochondrial ROS levels

STEM CELLS TRANSLATIONAL MEDICINE, 2020;

FI:6,429; Q1

Carrillo-Galvez, AB; Quintero, JE; Rodriguez, R; Menendez, ST; Gonzalez, MV; Blanco-Lorenzo, V; Allonca, E; Farias, VD; Gonzalez-Correa, JE; Erill-Sagales, N; Martinez-Zubiaurre, I; Hellevik, T; Sanchez-Hernandez, S; Munoz, P; Zurita, F; Martin, F; Rodrig

GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-beta

CELL DEATH & DISEASE, 2020;

FI:6,304; Q1

Bolivar-Galiano, F; Abad-Ruiz, C; Sanchez-Castillo, P; Toscano, M; Romero-Noguera, J

Frequent Microalgae in the Fountains of the Alhambra and Generalife: Identification and Creation of a Culture Collection

APPLIED SCIENCES-BASEL, 2020;

FI:2,474; Q2

Cozar, JM; Robles-Fernandez, I; Rodriguez-Martinez, A; Puche-Sanz, I; Vazquez-Alonso, F; Lorente, JA; Martinez-Gonzalez, LJ; Alvarez-Cubero, MJ

The role of miRNAs as biomarkers in prostate cancer

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2019;

FI:6,081; D1

Flores-Martin, JF; Perea, F; Exposito-Ruiz, M; Carretero, FJ; Rodriguez, T; Villamediana, M; Ruiz-Cabello, F; Garrido, F; Cozar-Olmo, JM; Aptsiauri, N

A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer

ANNALS OF SURGICAL ONCOLOGY, 2019;

FI:3,681; Q1

Moron, R; Galvez, J; Colmenero, M; Anderson, P; Cabeza, J; Rodriguez-Cabezas, ME

The Importance of the Microbiome in Critically Ill Patients: Role of Nutrition

NUTRIENTS, 2019;

FI:4,171; Q1

Garrido, F

MHC Class-I Loss and Cancer Immune Escape Introduction

MHC CLASS-I LOSS AND CANCER IMMUNE ESCAPE, 2019;

FI:2,126; Q2

Garrido, F

MHC/HLA Class I Loss in Cancer Cells

MHC CLASS-I LOSS AND CANCER IMMUNE ESCAPE, 2019;

FI:2,126; Q2

Aptsiauri, N; Ruiz-Cabello, F; Garrido, F

The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses

CURRENT OPINION IN IMMUNOLOGY, 2018;

FI:7,932; D1

Cozar, JM; Robles-Fernandez, I; Martinez-Gonzalez, LJ; Pascual-Geler, M; Rodriguez-Martinez, A; Serrano, MJ; Lorente, JA; Alvarez-Cubero, MJ

Genetic markers a landscape in prostate cancer

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2018;

FI:5,205; D1

Romero, I; Garrido, C; Algarra, I; Chamorro, V; Collado, A; Garrido, F; Garcia-Lora, AM

MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy

FRONTIERS IN IMMUNOLOGY, 2018;

FI:5,511; Q1

Pascual-Geler, M; Urquiza-Salvat, N; Cozar, JM; Robles-Fernandez, I; Rivas, A; Martinez-Gonzalez, LJ; Ocana-Peinado, FM; Lorente, JA; Alvarez-Cubero, MJ

The influence of nutritional factors on prostate cancer incidence and aggressiveness

AGING MALE, 2018;

FI:2,5; Q2

Garrido, MA; Rodriguez, T; Zinchenko, S; Maleno, I; Ruiz-Cabello, F; Concha, A; Olea, N; Garrido, F; Aptsiauri, N

HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15

IMMUNOGENETICS, 2018;

FI:2,094; Q3

Arrabal-Polo, MA; Arrabal-Martin, M; Mijan-Ortiz, JL; Vazquez-Alonso, F; Cozar-Olmo, JM

Assessing robot-assisted laparoscopic prostatectomy

LANCET, 2017;

FI:47,831; D1

Morote, J; Tabernero, AJ; Ossorio, JLA; Ciria, JP; Dominguez-Escrig, JL; Vazquez, F; Angulo, J; Lopez, FJ; de La Iglesia, R; Romero, J

Cognitive Function in Patients With Prostate Cancer Receiving Luteinizing Hormone-Releasing Hormone Analogues: A Prospective, Observational, Multicenter Study

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017;

FI:5,133; D1

Garrido, F; Ruiz-Cabello, F; Aptsiauri, N

Rejection versus escape: the tumor MHC dilemma

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017;

FI:4,711; Q1

Perea, F; Bernal, M; Sanchez-Palencia, A; Carretero, J; Torres, C; Bayarri, C; Gomez-Morales, M; Garrido, F; Ruiz-Cabello, F

The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration

INTERNATIONAL JOURNAL OF CANCER, 2017;

FI:6,513; Q1

Robles-Fernandez, I; Martinez-Gonzalez, LJ; Pascual-Geler, M; Cozar, JM; Puche-Sanz, I; Serrano, MJ; Lorente, JA; Alvarez-Cubero, MJ

Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness

PLOS ONE, 2017;

FI:2,806; Q1

Valderrama-Illana, P; Abad-Menor, F; Puche-Sanz, I; Pareja-Vilchez, M; Cozar-Olmo, JM

Penile Strangulation Caused by a Seal Ring

ARCHIVES OF SEXUAL BEHAVIOR, 2016;

FI:2,704; D1

Garrido, F; Aptsiauri, N; Doorduijn, EM; Lora, AMG; van Hall, T

The urgent need to recover MHC class I in cancers for effective immunotherapy

CURRENT OPINION IN IMMUNOLOGY, 2016;

FI:7,126; D1

Carretero, FJ; del Campo, AB; Flores-Martin, JF; Mendez, R; Garcia-Lopez, C; Cozar, JM; Adams, V; Ward, S; Cabrera, T; Ruiz-Cabello, F; Garrido, F; Aptsiauri, N

Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016;

FI:4,846; Q1

Aptsiauri, N; Jewett, A; Hurwitz, AA; Shurin, MR; Umansky, V

Redefining cancer immunotherapy-optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27-30, 2015, Ljubljana, Slovenia

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016;

FI:4,846; Q1

Garrido, F; Romero, I; Aptsiauri, N; Garcia-Lora, AM

Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype

INTERNATIONAL JOURNAL OF CANCER, 2016;

FI:5,531; Q1

Martin-Martin, L; Lopez, A; Vidriales, B; Caballero, MD; Rodrigues, AS; Ferreira, SI; Lima, M; Almeida, S; Valverde, B; Martinez, P; Ferrer, A; Candeias, J; Ruiz-Cabello, F; Buadesa, JM; Sempere, A; Villamor, N; Orfao, A; Almeida, J

Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile

ONCOTARGET, 2015;

FI:6,359; D1

Ortega, FG; Fernandez-Baldo, MA; Serrano, MJ; Messina, GA; Lorente, JA; Raba, J

Epithelial cancer biomarker EpCAM determination in peripheral blood samples using a microfluidic immunosensor based in silver nanoparticles as platform

SENSORS AND ACTUATORS B-CHEMICAL, 2015;

FI:4,097; D1

Ulzurrun E; Stephens C; Ruiz-Cabello F; Robles-Diaz M; Saenz-López P; Hallal H; Soriano G; Roman E; Fernandez MC; Lucena MI; Andrade RJ.

Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort

PLOS ONE, 2015;

FI:3,234; Q1

Alvarez-Cubero, MJ; Martinez-Gonzalez, LJ; Saiz, M; Carmona-Saez, P; Alvarez, JC; Pascual-Geler, M; Lorente, JA; Cozar, JM

Prognostic role of genetic biomarkers in clinical progression of prostate cancer

EXPERIMENTAL AND MOLECULAR MEDICINE, 2015;

FI:3,446; Q2

Matas-Cobos, AM; Redondo-Cerezo, E; Alegria-Motte, C; Martinez-Chamorro, A; Saenz-Lopez, P; Jimenez, P; Jimenez, MRC; Gonzalez-Calvin, JL; de Teresa, J; Osuna, FRC